Use of Non-Steroidal Antiinflammatory Drugs and Type-Specific Risk of Acute Coronary Syndrome

American Journal of Cardiology

Volumn 105, Issue 8, 2010, Pages 1102-1106

  Bueno, Héctor ^a   Bardají, Alfredo ^b   Patrignani, Paola ^c   Martín Merino, Elisa ^d   García Rodríguez, Luis A ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c UNIVERSITY OF CHIETI   (Italy)

^d Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; BODY MASS; CASE CONTROL STUDY; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; DYSLIPIDEMIA; HEALTH HAZARD; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SPAIN; ST SEGMENT ELEVATION; STRUCTURED QUESTIONNAIRE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFIDENCE INTERVALS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SPAIN;

EID: 77950370898     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.008     Document Type: Article

References (19)

1. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
2. García Rodríguez L.A., Varas-Lorenzo C., Maguire A., and González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109 (2004) 3000-3006
3. Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., Rimm E.B., Willett W.C., and Fuchs C.S. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
4. Hernández-Díaz S., Varas-Lorenzo C., and García Rodríguez L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98 (2006) 266-274
5. Helin-Salmivaara A., Virtanen A., Vesalainen R., Grönroos J.M., Klaukka T., Idänpään-Heikkilä J.E., and Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27 (2006) 1657-1663
6. García Rodríguez L.A., Taconnelli S.T., and Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52 (2008) 1628-1636
7. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
8. García-Dorado D., Castro-Beiras A., Díez J., Gabriel R., Gimeno-Blanes J.R., Ortiz de Landázuri M., Sánchez P.L., Fernández-Avilés F., and Grupos que Integran la Red RECAVA. Cooperative Cardiovascular Disease Research Network (RECAVA). Rev Esp Cardiol 61 (2008) 58-65
9. Lanas A., García-Rodríguez L.A., Arroyo M.T., Gomollon F., Feu F., Gonzalez Perez A., Zapata E., Bastida G., Rodrigo L., Santolaria S., Güell M., Martín de Argila C., Quintero E., Borda F., and Piqué J.M. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 55 (2006) 1731-1738
10. Clive D.M., and Stoff J.S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310 (1984) 563-572
11. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure?. A meta-analysis. Ann Intern Med 121 (1994) 289-300
12. Page J., and Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an unrecognized public health problem. Arch Intern Med 160 (2000) 777-784
13. Solomon D.H., Glynn R.J., Rothman K.J., Schneeweiss S., Setoguchi S., Mogun H., Avorn J., and Stürmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 59 (2008) 1097-1104
14. Patrono C., Coller B., Dalen J., Fuster V., Gent M., Harker L., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 126 (2004) 234S-264S
15. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., Di Gregorio P., Merciaro G., Patrono C., and Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
16. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., Taubert K.A., and American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
17. Watson D.J., Rhodes T., Cai B., and Guess H.A. Lower risk of thromboembolic events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162 (2002) 1105-1110
18. Rahme E., Pilote L., and LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162 (2002) 1111-1115
19. Capone M.L., Tacconelli S., Sciulli M.G., Anzellotti P., Di Francesco L., Merciaro G., Di Gregorio P., and Patrignani P. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322 (2007) 453-460